Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) PT at $16.70

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have earned an average rating of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $16.70.

A number of brokerages have recently issued reports on YMAB. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Wedbush reissued an “outperform” rating and set a $23.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Oppenheimer dropped their price target on Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research report on Wednesday. Bank of America lowered Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research report on Tuesday, April 22nd. Finally, HC Wainwright dropped their price target on Y-mAbs Therapeutics from $22.00 to $12.00 and set a “buy” rating on the stock in a research report on Friday, March 21st.

Y-mAbs Therapeutics Stock Up 6.2%

Shares of Y-mAbs Therapeutics stock opened at $4.10 on Thursday. The stock’s fifty day moving average is $4.47 and its 200-day moving average is $7.05. The firm has a market capitalization of $185.64 million, a PE ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics has a 12-month low of $3.55 and a 12-month high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. Analysts expect that Y-mAbs Therapeutics will post -0.65 EPS for the current year.

Insiders Place Their Bets

In other news, insider Thomas Gad sold 10,810 shares of the company’s stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

Several large investors have recently made changes to their positions in YMAB. Barclays PLC boosted its stake in shares of Y-mAbs Therapeutics by 433.4% during the 3rd quarter. Barclays PLC now owns 69,222 shares of the company’s stock worth $910,000 after acquiring an additional 56,244 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Y-mAbs Therapeutics by 10.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after acquiring an additional 2,854 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company’s stock worth $139,000 after acquiring an additional 4,163 shares in the last quarter. Principal Financial Group Inc. boosted its stake in shares of Y-mAbs Therapeutics by 9.4% during the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company’s stock worth $174,000 after acquiring an additional 1,903 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Y-mAbs Therapeutics by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock worth $2,228,000 after acquiring an additional 4,963 shares in the last quarter. Institutional investors own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.